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expanded-spectrum β-lactam. antibiotics Extended-
spectrum β-lactamases (ESBLs) mostly disseminate and 
persist in hospital settings. During the last decade, how-
ever, CTX-M-type ESBLs have emerged in the community 
setting among E. coli isolates, on plasmids that frequently 
bear additional resistance determinants. Consequently, 
ESBL-mediated resistance has consistently increased in 
E. coli in the community setting.1 This increase in resist-
ance within the community is a public health concern. 
There are limited data available in Turkey regarding 
ESBLs isolated from community onset UTIs. Our aim was 
to investigate the ESBLs among E. coli isolates from com-
munity acquired UTIs in the European part of Turkey (the 
Thrace area).
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Extended spectrum β-lactamase (ESBL) producing Escherichia coli has been an emerging etiologic agent in 
the community acquired infections. We investigated the occurrence of ESBL producing E. coli isolated 
from patients admitted with community acquired urinary tract infection (UTI) to the hospital of the 
Trakya University, Turkey during 2006. Eleven single patient isolates of E. coli harboring ESBL were identi-
fied among 30 E. coli isolated from patients admitted with symptoms corresponding to upper UTI. CTX-M 
type ESBLs were detected in all 11 ESBL-producers by isoelectric focusing and polymerase chain reaction 
screening. Sequence analysis revealed CTX-M-1 in one isolate, CTX-M-3 in three isolates and CTX-M-15 
in seven isolates. ESBL-producing E. coli isolated from community acquired UTIs are widespread in the 
European part of Turkey.
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Introduction
Community acquired urinary tract infections (UTIs) 
are generally caused by Escherichia coli susceptible to 
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Materials and methods
Isolates and clinical data
ESBL-producing E. coli isolated from patients admitted 
with symptoms corresponding to upper UTIs to the 
hospital of the Trakya University, Turkey in 2006 were 
included in the study. Clinical data were collected retro-
spectively by chart review. Community acquired infection 
was defined as (1) infections that occurred less than 
48 hours after admission to the hospital in patients who 
had not been previously been hospitalized within the pre-
ceding 30 days; (2) did not fulfill the criteria for hospital 
acquired infections as delineated by the Centers for Dis-
ease Control and Pre vention; and (3) occurred in patients 
who were not transferred from an outside hospital. After 
performing urine and blood cultures, antibiotic treatment 
was started empirically on admission. Treatments were 
modified according to the culture results. On the 4th day 
of therapy, urine culture was performed as a control.
Antibiotic susceptibility testing and detection of 
ESBL-producing isolates
Identification, antibiotic susceptibility, and the minimal 
inhibitory concentration values of the strains were deter-
mined using the Vitek2 system (bioMerieux SA, Marcy-
l’Etoile, France) and the results interpreted according to 
the guidelines of the Clinical and Laboratory Standards 
Institute. A double-disk synergy test was used to screen 
ESBL production in E. coli isolates.
Isoelectric focusing
Crude extracts of the isolates were prepared by sonication 
and analytic isoelectric focusing (IEF) performed using a 
Model 111 Mini IEF Cell (Bio-Rad, Hercules, CA, USA) as 
described previously.2 Enzymes were detected by nitroce-
fin (0.1 nM) overlay (Calbiochem US and Canada) and 
pI values were estimated relative to the known enzymes 
(TEM-1, pI = 5.4: SHV-1, pI = 7.6; OXA-14, pI = 6.2) used in 
the experiment.
Polymerase chain reaction
DNAs for β-lactamase screening by polymerase chain 
reaction (PCR) were extracted by incubating dense bacte-
rial suspensions at 95ºC for 10 minutes and removing 
the debris by centrifugation for 10 minutes at 12,000 g as 
described.3 PCR was accomplished in 50 μL reaction,with 
using 5 μL of DNA extract, 1 ˜  buffer, 1.5 mM of MgCl2, 
0.8 mM of dNTPs, 50 pmol of each primers and 1.5 U of 
Taq polymerase (Fermentas, Lithuania). Amplification was 
accomplished after a 5-minute denaturation at 95ºC, fol-
lowed by 40 cycles of denaturation at 94ºC for 30 seconds, 
annualing at 55ºC for 60 seconds and extension at 72ºC 
for 60 seconds. The PCR products were run on a 1.5% aga-
rose gel and results visualized using a UV lamp. A 496 bp 
internal sequence from the blaCTX-M-1 phylogenetic sub-
group was amplified using forward primer: 5-ATG TGC 
AGC ACC AGT AAA GT-3 and reverse primer: 5-CCC 
CCA CAA CCC AGG AAG CA-3.
Gene sequencing
Sequence analysis was performed with the same primers 
on both strands of the PCR products, purified using the 
High Pure PCR Product Purification Kit (Roche Diagno-
stics, Basel, Switzerland). CTX-M types were further con-
firmed by amplification and sequencing on both sides of 
the full length bla genes (876 bp) using forward primer 5-
ATG GTT AAA AAA TCA CTG CGC-3 and reverse primer 
5-TTA CAA ACC GTC GGT GAC GAT-3. PCR amplifica-
tion was accomplished as mentioned above, except that 
the extension time was 2 minutes.
Sequence analysis was done using the dye terminator 
cycle sequencing method and an ABI Prism BigDye Ter-
minator kit (Applied Biosystems, Foster City, CA, USA). 
The assay was carried out according to a standard proto-
col. Data were collected on an ABI 377 automated fluo-
rescence sequencer (Applied Biosystems).
Results
During the study period, a total of 60 cases of community 
acquired UTI were admitted. An etiologic agent was isolated 
from 50 cases. Of all the isolates, 30 (60.0%) were E. coli. ESBL 
was detected in 11 (36.7%) of the E. coli isolates by the double-
disk synergy test. Etiologic agents identified from urine cul-
tures of the other patients were as follows: Enterococcus faecalis 
in 10 patients, Enterococcus faecium in four patients, and 
Klebsiella pneumoniae in six patients. The ESBL phenotype was 
not detected in the K. pneumoniae isolates. All the E. coli iso-
lates that did not produce ESBL, along with K. pneumoniae, 
were susceptible to extended-spectrum cephalosporins.
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CTX-M type ESBLs were detected in all 11 ESBL-
producers by IEF and PCR screening. No other β-lactama-
ses were detected. The primers used for screening were 
specific to the CTX-M-1 phylogenetic subgroup, and se-
quence analysis of the internal fragments amplified by 
these primers further suggested that the bla genes be-
longed to the same family. For the full-length amplifica-
tion and sequencing of bla genes, we designed the 
outermost primers specific to the CTX-M-1 subgroup. 
Subsequently, sequence analysis revealed CTX-M-1 in 
one isolate, CTX-M-3 in three isolates and CTX-M-15 in 
seven isolates. CTX-M types, minimal inhibitory concen-
tration values for antibiotics, blood culture results and 
the treatment data for the ESBL-producing E. coli are 
shown in the Table. None of the patients with ESBL-
producing E. coli had a history of contact with health care 
centers, or admission to hospital, although five patients 
had a history of antibiotic exposure in the last 2 months. 
The antibiotics used by the five patients were second 
generation cephalosporins (3 patients) and fluoroqui-
nolones (2 patients). None of the patients had recurrent 
UTIs.
ESBL-producing E. coli was isolated from both urine 
and blood from four patients. The bloodstream isolates 
had the same resistance phenotypes as the urine isolates. 
On admission to the hospital, the patients had been given 
ceftriaxone empirically. Treatment was then changed ac-
cording to the culture results. The three patients with 
ciprofloxacin-susceptible isolates and a negative blood 
cultures were successfully treated with ciprofloxacin; oth-
erwise, imipenem was antibiotic of choice. Urine cultures 
were negative in all patients obtained on the 4th day of the 
antibiotic treatment (control cultures). However, antibi-
otics were administered for 14 days, and all of the patients 
improved clinically.
Discussion
ESBL-producing E. coli has been detected among nosoco-
mial infections worldwide, but in recent years this micro-
organism has also been reported in community acquired 
infections.4–7 Although we do not know the exact preva-
lence of these organisms in our country, our findings sug-
gest that ESBL producers have already begun to disseminate 
throughout the European part of Turkey. A recent publi-
cation reported that CTX-M is common among the ESBL-
producing E. coli isolates obtained from community 
acquired UTIs in Izmir, a city in West Anatolia.8 The rate 
of ESBL-producing E. coli was found to be 21% in that 
study. We also found this rate to be quite high (36.7%) and, 
Table. CTX-M types, minimal inhibitory concentration values for antibiotics of expanded-spectrum beta-lactam antibiotics-
producing Escherichia coli, blood culture results and patient treatment data
Case β-lactamase AK SAM ATM FEP CAZ CRO CIP GN IPM MEM TZP SXT
 Blood 
Treatment
              culture 
 1 CTX-M-1 < 2 > 32 4 32 < 1 > 64 < 0.25 < 1 < 1 < 0.25 64  < 20 Negative Ciprofloxacin
 2 CTX-M-3 8 > 32 > 64 32 > 64 > 64 > 4 > 16 < 1 < 0.25 64 > 320 Positive Imipenem
 3 CTX-M-3 8 > 32 > 64 32 16 > 64 > 4 2 < 1 < 0.25 8 > 320 Negative Imipenem
 4 CTX-M-3 16 > 32 < 1 < 1 < 1 > 64   0.50 4 < 1 < 0.25 64 > 320 Negative Ciprofloxacin
 5 CTX-M-15 16 32 2 < 1 4 > 64 > 4 < 1 < 1 < 0.25 8 > 320 Negative Imipenem
 6 CTX-M-15 16 > 32 < 1 < 1 < 1 > 64 > 4 4 < 1 < 0.25 < 4 > 320 Positive Imipenem
 7 CTX-M-15 8 > 32 > 64 8 16 > 64 > 4 > 16 < 1 < 0.25 8 > 320 Positive Imipenem
 8 CTX-M-15 16 > 32 > 64 4 16 > 64 > 4 2 < 1 < 0.25 8 > 320 Negative Imipenem
 9 CTX-M-15 < 2 32 16 > 64 4 > 64 < 0.25 < 1 < 1 < 0.25 < 4  40 Negative Ciprofloxacin
10 CTX-M-15 < 2 > 32 32 4 < 1 > 64   0.50 < 1 < 1 < 0.25 < 4  < 20 Positive Imipenem
11 CTX-M-15 16 > 32 16 4 4 > 64 > 4 4 < 1 < 0.25 64 > 320 Negative Imipenem
AK = Amikacin; ATM = aztreonam; CAZ = ceftazidime; CIP = ciprofloxacin; CRO = ceftriaxone; FEP = cefepime; GN = gentamycin; IPM = 
imipenem; MEM = meropenem; SAM = sulbactam-ampicillin; SXT = co-trimoxazole; TZP = piperacillin-tazobactam.
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among these ESBLs, the most prevalent type was CTX-
M-15. Such a predominance of the CTXM-15 enzyme was 
also reported in the study from Turkey,8 and from other 
European countries.9–11
Genes encoding ESBLs are usually located on plasmids 
carrying other resistance determinants for aminoglyco-
sides, trimethoprim, sulfonamides, and quinolones. Resist-
ance to quinolones was detected at a high rate (7/11) among 
our isolates. Some studies have reported a lower prevalence 
of resistance to quinolones and aminoglycosides,12 whereas 
others have reported this rate as high as 50% among com-
munity acquired CTX-M-producing E. coli isolates.10 
There are concerns about the use of quinolones in an in-
fection caused by ESBL-producing Enterobacteriaceae, 
even if it is susceptible to this class of antibiotics.13,14 
Therefore, high rates of quinolone and co-trimoxazole re-
sistance among ESBL-producing urinary isolates is a signif-
icant complication that unavoidably increases carbapenem 
utilization, especially in the community setting. In this 
study, however, of the four patients with quinolone sus-
ceptible isolates, three were treated successfully with cip-
rofloxacin, signifying the use of quinolones in UTIs where 
the isolate is susceptible to this antibiotic. Carbap enems 
have been shown to be associated with the lowest mor-
tality of any drug class when used against infections by 
ESBL-producing organisms. Mortality in patients with 
blood culture-positive, ESBL-producing organisms was 
less than 10% when patients received either imipenem or 
meropenem.14 Non-β-lactam drugs, such as quinolones, 
trimethoprim-sulfamethoxazole, and aminoglycosides, are 
not adequate as a first line therapy for serious infections 
such as bacteremia.15 We also selected carbapenem ther-
apy for four patients with positive culture for both urine 
and blood. In conclusion, our results indicate that ESBL-
producing E. coli isolated from community acquired UTIs 
are widespread in the European part of Turkey, and iden-
tify the predominant types as CTX-M β-lactamases. We 
can say that ESBL-producing bacteria are a problem not 
only for hospital acquired infections, but also for commu-
nity acquired infections in the Thrace region of Turkey.
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